Bolder BioTechnology

Bolder BioTechnology, Inc. is a clinical-stage protein therapeutics company dedicated to providing patients with treatments that are easier to use, safer, and more effective for their conditions. Most protein drugs require frequent dosing, often daily, particularly via injection. There is a significant unmet medical need for innovative protein drugs that do not require frequent administration. The company’s products address this need. By utilizing advanced protein engineering and targeted bioconjugation technologies, the company creates long-acting and more effective versions of FDA-approved protein drugs (Enhanced Protein Therapeutics™), which are administered less frequently—such as weekly to monthly—but demonstrate equivalent or better efficacy compared to currently available products. Our diversified product pipeline targets markets with annual sales exceeding $20 billion, including treatments for blood and endocrine disorders, cancer, and infectious diseases.